Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Change in Receivables (2016 - 2025)

Marimed (MRMD) has disclosed Change in Receivables for 12 consecutive years, with -$12000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Change in Receivables rose 33.33% to -$12000.0 in Q1 2025 year-over-year; TTM through Sep 2025 was $1.2 million, a 62.45% decrease, with the full-year FY2024 number at $1.2 million, down 61.8% from a year prior.
  • Change in Receivables was -$12000.0 for Q1 2025 at Marimed, down from $1.2 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $5.0 million in Q3 2022 to a low of -$3.4 million in Q3 2021.
  • A 5-year average of $646764.7 and a median of -$7000.0 in 2022 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: skyrocketed 3022.86% in 2022, then crashed 2314.29% in 2023.
  • Marimed's Change in Receivables stood at -$70000.0 in 2021, then surged by 3022.86% to $2.0 million in 2022, then skyrocketed by 57.14% to $3.2 million in 2023, then plummeted by 62.18% to $1.2 million in 2024, then tumbled by 100.99% to -$12000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Change in Receivables are -$12000.0 (Q1 2025), $1.2 million (Q4 2024), and $28000.0 (Q3 2024).